FY 2014 Omnibus HR 3547
FY 2014 Continuing Resolution H J Res 106 PL 113-73
FY 2014 Continuing Resolution H J Res 59 PL 113-67
FY 2015 Budget, H Con Res 96 (no Senate Companion at this time)
HJ Res 124 Continuing Appropriations Resolution, 2015
In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs
Health care reform implementation; the 340B program of the Health Resources and Services Administration (HRSA), specifically 340B drug pricing program issues, including program expansion and specific issues include: HRSA oversight, definition of patient, the ACA's expansion of covered 340B entities.
HR 4302 Protecting Access to Medicare Act of 2014 - Public Law No: 113-93
In the above the specific issues included potential Medicare offsets that might be applied to prescription drugs
H.R.4187 -- Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014
Implementation of the "GAIN" provisions/Title VIII of the Food and Drug Administration Safety and Innovation Act (FDASIA) - PL 112-144; antibiotic product development incentive, limited population antibiotic product (LPAD) and breakpoint legislation
HR 3742 -- the Antibiotic Development to Advance Patient Treatment Act of 2013
H.R.4187 -- Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014
antibiotic product incentives for possible inclusion in the House "21st Century Cures" effort
Duration: January 3, 2013
to
December 29, 2014
General Issues: Budget/Appropriations , Health Issues , Medicare/Medicaid , Pharmacy
Spending: about $480,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2013: U.S. Senate, House of Representatives
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2014
SLC Health Strategies, LLC terminated an engagement in which they represented Cubist Pharmaceuticals, Inc. on Dec. 29, 2014.
Original Filing: 300692321.xml
Lobbying Issues
FY 2014 Omnibus HR 3547
FY 2014 Continuing Resolution H J Res 106 PL 113-73
FY 2014 Continuing Resolution H J Res 59 PL 113-67
FY 2015 Budget, H Con Res 96 (no Senate Companion at this time)
HJ Res 124 Continuing Appropriations Resolution, 2015
In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs
Agencies Lobbied
U.S. Senate
Lobbying Issues
Health care reform implementation; the 340B program of the Health Resources and Services Administration (HRSA), specifically 340B drug pricing program issues, including program expansion and specific issues include: HRSA oversight, definition of patient, the ACA's expansion of covered 340B entities.
Agencies Lobbied
U.S. Senate
Lobbying Issues
HR 4302 Protecting Access to Medicare Act of 2014 - Public Law No: 113-93
In the above the specific issues included potential Medicare offsets that might be applied to prescription drugs
H.R.4187 -- Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of the "GAIN" provisions/Title VIII of the Food and Drug Administration Safety and Innovation Act (FDASIA) - PL 112-144; antibiotic product development incentive, limited population antibiotic product (LPAD) and breakpoint legislation
HR 3742 -- the Antibiotic Development to Advance Patient Treatment Act of 2013
H.R.4187 -- Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014
antibiotic product incentives for possible inclusion in the House "21st Century Cures" effort
Agencies Lobbied
U.S. Senate
3rd Quarter, 2014
In Q3, SLC Health Strategies, LLC lobbied for Cubist Pharmaceuticals, Inc. , earning $60,000. The report was filed on Oct. 19, 2014.
Original Filing: 300682379.xml
Lobbying Issues
FY 2014 Omnibus HR 3547
FY 2014 Continuing Resolution H J Res 106 PL 113-73
FY 2014 Continuing Resolution H J Res 59 PL 113-67
FY 2015 Budget, H Con Res 96 (no Senate Companion at this time)
HJ Res 124 Continuing Appropriations Resolution, 2015
In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs
Agencies Lobbied
U.S. Senate
Lobbying Issues
Health care reform implementation; the 340B program of the Health Resources and Services Administration (HRSA), specifically 340B drug pricing program issues, including program expansion and specific issues include: HRSA oversight, definition of patient, the ACA's expansion of covered 340B entities.
Agencies Lobbied
U.S. Senate
Lobbying Issues
HR 4302 Protecting Access to Medicare Act of 2014 - Public Law No: 113-93
In the above the specific issues included potential Medicare offsets that might be applied to prescription drugs
H.R.4187 -- Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of the "GAIN" provisions/Title VIII of the Food and Drug Administration Safety and Innovation Act (FDASIA) - PL 112-144; antibiotic product development incentive, limited population antibiotic product (LPAD) and breakpoint legislation
HR 3742 -- the Antibiotic Development to Advance Patient Treatment Act of 2013
H.R.4187 -- Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014
antibiotic product incentives for possible inclusion in the House "21st Century Cures" effort
Agencies Lobbied
U.S. Senate
2nd Quarter, 2014
In Q2, SLC Health Strategies, LLC lobbied for Cubist Pharmaceuticals, Inc. , earning $60,000. The report was filed on July 21, 2014.
Original Filing: 300664604.xml
Lobbying Issues
FY 2014 Omnibus HR 3547
FY 2014 Continuing Resolution H J Res 106 PL 113-73
FY 2014 Continuing Resolution H J Res 59 PL 113-67
FY 2015 Budget, H Con Res 96 (no Senate Companion at this time)
In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs
Agencies Lobbied
U.S. Senate
Lobbying Issues
Health care reform implementation; the 340B program of the Health Resources and Services Administration (HRSA), specifically 340B drug pricing program issues, including program expansion and specific issues include: HRSA oversight, definition of patient, the ACA's expansion of covered 340B entities.
Agencies Lobbied
U.S. Senate
Lobbying Issues
HR 4302 Protecting Access to Medicare Act of 2014 - Public Law No: 113-93
In the above the specific issues included potential Medicare offsets that might be applied to prescription drugs H.R.4187 -- Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of the "GAIN" provisions/Title VIII of the Food and Drug Administration Safety and Innovation Act (FDASIA) - PL 112-144; antibiotic product development incentive, limited population antibiotic product (LPAD) and breakpoint legislation
HR 3742 -- the Antibiotic Development to Advance Patient Treatment Act of 2013
H.R.4187 -- Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014
antibiotic product incentives for possible inclusion in the House "21st Century Cures" effort
Agencies Lobbied
U.S. Senate
1st Quarter, 2014
In Q1, SLC Health Strategies, LLC lobbied for Cubist Pharmaceuticals, Inc. , earning $60,000. The report was filed on April 21, 2014.
Original Filing: 300646592.xml
Lobbying Issues
FY 2014 Omnibus HR 3547
FY 2014 Continuing Resolution H J Res 106 PL 113-73
FY 2014 Continuing Resolution H J Res 59 PL 113-67
In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Health care reform implementation; the 340B program of the Health Resources and Services Administration (HRSA), specifically 340B drug pricing program issues, including program expansion and specific issues include: HRSA oversight, definition of patient, the ACA's expansion of covered 340B entities.
Agencies Lobbied
U.S. Senate
Lobbying Issues
HR 4302 Protecting Access to Medicare Act of 2014 - Public Law No: 113-93
In the above the specific issues included potential Medicare offsets that might be applied to prescription drugs
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Implementation of the "GAIN" provisions/Title VIII of the Food and Drug Administration Safety and Innovation Act (FDASIA) - PL 112-144; antibiotic product development incentive, limited population antibiotic product (LPAD) and breakpoint legislation
HR 3742 -- the Antibiotic Development to Advance Patient Treatment Act of 2013
H.R.4187 -- Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2013
In Q4, SLC Health Strategies, LLC lobbied for Cubist Pharmaceuticals, Inc. , earning $60,000. The report was filed on Jan. 21, 2014.
Original Filing: 300623360.xml
Lobbying Issues
S. Con. Res. 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014
H. Con. Res. 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY 2015 through 2033
H. J. Res. 59 -- Continuing Appropriations Resolution, 2014
In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs
Agencies Lobbied
U.S. Senate
Type of Issue
Budget/Appropriations/Medicaid
Lobbying Issues
Health care reform implementation; the 340B program of the Health Resources and Services Administration (HRSA), specifically 340B drug pricing program issues, including program expansion and specific issues include: HRSA oversight, definition of patient, the ACA's expansion of covered 340B entities.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of the "GAIN" provisions/Title VIII of the Food and Drug Administration Safety and Innovation Act (FDASIA) - PL 112-144; antibiotic product development incentive, limited population antibiotic product (LPAD) and breakpoint legislation; pharmaceutical track and trace legislation or as packaged with/tied to pharmaceutical compounding legislation: HR. 1919 - Safeguarding America's Pharmaceutical Act of 2013, HR 3204 - Drug Quality and Security Act, HR 2186 VALID Compounding Act, and S. 959 Pharmaceutical Compounding Quality and Accountability Act; HR 3742, the Antibiotic Development to Advance Patient Treatment Act of 2013
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2013
In Q3, SLC Health Strategies, LLC lobbied for Cubist Pharmaceuticals, Inc. , earning $60,000. The report was filed on Oct. 20, 2013.
Original Filing: 300601383.xml
Lobbying Issues
S. Con. Res. 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014
H. Con. Res. 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY 2015 through 2033
H. J. Res. 59 -- Continuing Appropriations Resolution, 2014
In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs
Agencies Lobbied
U.S. Senate
Type of Issue
Budget/Appropriations/Medicaid
Lobbying Issues
Health care reform implementation; the 340B program of the Health Resources and Services Administration (HRSA), specifically 340B drug pricing program issues, including program expansion and specific issues include: HRSA oversight, definition of patient, the ACA's expansion of covered 340B entities.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of the "GAIN" provisions/Title VIII of the Food and Drug Administration Safety and Innovation Act (FDASIA) - PL 112-144; antibiotic product development incentive, limited population antibiotic product (LPAD) and breakpoint legislation; pharmaceutical track and trace legislation or as packaged with/tied to pharmaceutical compounding legislation: HR. 1919 - Safeguarding America's Pharmaceutical Act of 2013, HR 3204 - Drug Quality and Security Act, HR 2186 VALID Compounding Act, and S. 959 Pharmaceutical Compounding Quality and Accountability Act
Agencies Lobbied
U.S. Senate
2nd Quarter, 2013
In Q2, SLC Health Strategies, LLC lobbied for Cubist Pharmaceuticals, Inc. , earning $60,000. The report was filed on July 19, 2013.
Original Filing: 300579607.xml
Lobbying Issues
S. Con. Res. 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014
H. Con. Res. 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY 15 through 2033
In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs
Agencies Lobbied
U.S. Senate
Lobbying Issues
Health care reform implementation; the 340B program of the Health Resources and Services Administration (HRSA), specifically 340B drug pricing program issues, including program expansion and specific issues include: HRSA oversight, definition of patient, the ACA's expansion of covered 340B entities
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. Con. Res 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014
H. Con. Res. 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY '15 through 2033
In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of the "GAIN" provisions/Title VIII of the Food and Drug Administration Safety and Innovation Act (FDASIA) - PL 112-144; antibiotic product development incentive, limited population antibiotic product (LPAD) and breakpoint legislation; pharmaceutical track and trace legislation (HR 1919 -- Safeguarding America's Pharmaceutical Act of 2013)
Agencies Lobbied
U.S. Senate
1st Quarter, 2013
In Q1, SLC Health Strategies, LLC lobbied for Cubist Pharmaceuticals, Inc. , earning $60,000. The report was filed on April 21, 2013.
Original Filing: 300558872.xml
Lobbying Issues
S. Con. Res 8 -- Concurrent Resolution on the Budget For Fiscal Year 2014
H Con Res 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY 15 through 2033
HR 933 -- Consolidated and Further Continuing Appropriations Act, 2013
In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs
Agencies Lobbied
U.S. Senate
Type of Issue
Budget/Appropriations/Medicaid
Lobbying Issues
Health care reform implementation; the 340B program of the Health Resources and Services Administration (HRSA), specifically 340B drug pricing program issues, including program expansion and specific issues include HRSA oversight, definition of patient, the ACA's expansion of covered 340B entities
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of the "GAIN" provisions/Title VIII of the Food and Drug Administration Safety and Innovation Act (FDASIA) - PL - 112-144; antibiotic product development incentive and limited population antibiotic product (LPAD) legislation; pharmaceutical trace and trace legislation; and S. 622 - Animal Drug and Animal Generic Drug User Fee Reauthorization Act of 2013 (specifically in regards to potential antibiotic-related provisions)
Agencies Lobbied
U.S. Senate
1st Quarter, 2013
SLC Health Strategies, LLC filed a lobbying registration on Jan. 19, 2013 to represent Cubist Pharmaceuticals, Inc., effective Jan. 3, 2013.
Original Filing: 300535885.xml
Issue(s) they said they’d lobby about: Medicare and Medicaid coverage/reforms/budget, antibiotic issues, prescription drug/Food and Drug Administration matters, and health care reform implementation .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...